Literature DB >> 22550411

Sequential antibiotic therapy: Effective cost management and patient care.

L A Mandell1, M G Bergeron, M J Gribble, P J Jewesson, D E Low, T J Marrie, L E Nicolle.   

Abstract

The escalating costs associated with antimicrobial chemotherapy have become of increasing concern to physicians, pharmacists and patients alike. A number of strategies have been developed to address this problem. This article focuses specifically on sequential antibiotic therapy (sat), which is the strategy of converting patients from intravenous to oral medication regardless of whether the same or a different class of drug is used. Advantages of sat include economic benefits, patient benefits and benefits to the health care provider. Potential disadvantages are cost to the consumer and the risk of therapeutic failure. A critical review of the published literature shows that evidence from randomized controlled trials supports the role of sat. However, it is also clear that further studies are necessary to determine the optimal time for intravenous to oral changeover and to identify the variables that may interfere with the use of oral drugs. Procedures necessary for the implementation of a sat program in the hospital setting are also discussed.

Entities:  

Keywords:  Cost effectiveness; Intravenous antibiotic therapy; Oral antibiotic therapy; Quality of life; Sequential antibiotic therapy

Year:  1995        PMID: 22550411      PMCID: PMC3327940          DOI: 10.1155/1995/165848

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  62 in total

1.  Simple ways to promote cost containment.

Authors:  D M Bunz; L Frighetto; S Gupta; P J Jewesson
Journal:  DICP       Date:  1990-05

2.  Cost-effectiveness and value of an IV switch.

Authors:  P Jewesson
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  High-dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in children.

Authors:  Y J Bryson; J D Connor; M LeClerc; S T Giammona
Journal:  J Pediatr       Date:  1979-04       Impact factor: 4.406

4.  Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gram-negative infections.

Authors:  P Chayakul; S Krisanapan; S Kalnauwakul
Journal:  J Med Assoc Thai       Date:  1993-01

5.  Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.

Authors:  R J Fass; J F Plouffe; J A Russell
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

6.  Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis.

Authors:  C G Prober; A S Yeager
Journal:  J Pediatr       Date:  1979-07       Impact factor: 4.406

7.  Pharmacokinetic considerations in quinolone therapy.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  1993 Mar-Apr       Impact factor: 4.705

8.  Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days.

Authors:  J R Johnson; M F Lyons; W Pearce; P Gorman; P L Roberts; N White; P Brust; R Olsen; J W Gnann; W E Stamm
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

9.  Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.

Authors:  P L Gaut; W C Carron; W T Ching; R D Meyer
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

10.  High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections.

Authors:  G M Auten; L C Preheim; M Sookpranee; M J Bittner; T Sookpranee; A Vibhagool
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more
  13 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  A multidisciplinary hospital-based antimicrobial use program: Impact on hospital pharmacy expenditures and drug use.

Authors:  S Salama; C Rotstein; L Mandell
Journal:  Can J Infect Dis       Date:  1996-03

3.  Strategies for controlling antibiotic use in a tertiary-care paediatric hospital.

Authors:  S A Diamond; B J Hales
Journal:  Paediatr Child Health       Date:  1997-05       Impact factor: 2.253

Review 4.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis.

Authors:  Ina Willemsen; Ben Cooper; Carin van Buitenen; Marjolein Winters; Gunnar Andriesse; Jan Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 6.  Cost effectiveness of quinolones in hospitals and the community.

Authors:  P Davey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 7.  Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.

Authors:  D Nathwani
Journal:  Drugs       Date:  2000       Impact factor: 9.546

8.  Intravenous and oral antibiotics in respiratory tract infection: an international observational study of hospital practice.

Authors:  J Cooke; M Kubin; T Morris; J Ribas; I Krämer; W Kämmerer; R Fornaini; A C Ballet; P P Sagnier
Journal:  Pharm World Sci       Date:  2002-12

9.  Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign.

Authors:  Ludovico Furlan; Luca Erba; Lucia Trombetta; Roberto Sacco; Giorgio Colombo; Giovanni Casazza; Monica Solbiati; Nicola Montano; Chiara Marta; Rodolfo Sbrojavacca; Francesco Perticone; Gino Roberto Corazza; Giorgio Costantino
Journal:  Intern Emerg Med       Date:  2018-10-08       Impact factor: 3.397

10.  Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.

Authors:  Raquel K Belforti; Tara Lagu; Sarah Haessler; Peter K Lindenauer; Penelope S Pekow; Aruna Priya; Marya D Zilberberg; Daniel Skiest; Thomas L Higgins; Mihaela S Stefan; Michael B Rothberg
Journal:  Clin Infect Dis       Date:  2016-04-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.